re f i n e m e nt will be re q u i red be fo re a final re co m m e n d at i o n of a standard i zed drug release method can be made.Fo r these dosage fo rm s,a brief summary of the state -o f -t h e -a rt kn owledge is provided to guide further deve l o p m e nt .Du e to the diffe re nt chara cte ristics of the nove l / s pecial dosage fo rms and their sites and modes of applicat i o n ,it is essent i a l t h at apparatus select i o n ,co m position of the dissolution m e d i u m ,a g i t ation (flow rate) and te m pe rat u re be give n a p p ro p ri ate co n s i d e ration during method design.I n i n s t a n ces where a co m pendial (e. g.U S P,Ph . Eu r. ,Ph . J a p. ) m e t h od is employed for in vitro drug release te s t i n g,t h e ex pe ri m e ntal test co n d i t i o n s,q u a l i f i cations and va l i d at i o n s teps should co n fo rm to those discussed in the FIP and FDA Guidelines on dissolution testing (1, 2 ) .
In genera l ,co m pendial apparatus and methods should be used as a first approach in drug deve l o p m e nt .To avo i d u n n e ce s s a ry pro l i fe ration of equipment and method d e s i g n ,m od i f i cations of co m pendial equipment or deve l o pm e nt or use of alte rn at i ve equipment should be co n s i d e re d only when it has been proven that co m pendial set up doe s not provide meaningful data for a given (new) dosage fo rm . Qu a l i f i cation and va l i d ation effo rts would include those q u o ted above (1, 2) and would be ex pe cted to demonstrate t h at the new method is scient i f i cally sound and guara nte e s a c c u rate,p recise and re p roducible dat a ,a s s u res acce p t a b l e d rug prod u ct quality and allows for some inte rp re t ation of the prod u ct's in vivo pe rfo rm a n ce.
In some ca s e s,the method used in the early phase of p rod u ct / fo rm u l ation deve l o p m e nt could be diffe re nt from the final test proce d u re utilized for co nt rol of the prod u ct quality. I n d e e d,m e t h ods used for fo rm u l ation screening or understanding of the release mechanism may simply be impra ct i ca l for a quality co nt rol env i ro n m e nt .It is essential that with the a c c u m u l ation of ex pe ri e n ce,the early method be cri t i ca l l y re eva l u ated and po te ntially simplified,giving pre fe re n ce to co m pendial apparat u s.The final method may not nece s s a ri l y closely imitate the in vivo env i ro n m e nt,but should still test the key pe rfo rm a n ce indicators of the fo rm u l at i o n .
Dosage Fo rms for Which a Specific Me t h od Can Be Reco m m e n d e d O ral Su s pensions (for sys temic use)
In genera l ,the ro t ating paddle method utilizing an aqueous dissolution medium is the re commended method for dissolution testing of suspe n s i o n s.To obtain re p re s e nt at i ve samples,p rod u ct pre p a ration should fo l l ow a standardi zed proce d u re based on shaking or mixing.Sa m p l e we i g ht / volume should re f l e ct a ty p i cal dose of the prod u ct . Me t h od para m e ters such as sample int rod u ction and agitation rate should be established on the basis of the visco s i ty and co m position of the suspension mat ri x .The sample i nt rod u ction technique must be accurate,p recise and re p rod u c i b l e.Even though oral suspensions of any visco s i ty would be ex posed to similar ranges of shearing fo rces afte r a d m i n i s t ration in vivo,the in vitro agitation rate should be s e l e cted to facilitate discri m i n ation be tween batches with d i f fe re nt release pro pe rt i e s.
For low visco s i ty suspe n s i o n s,an accurate dose can be d e l i ve red to the bo t tom of the dissolution vessel using a vo l u m e t ric pipe t te.A slow agitation rate of 25 rpm is generally re commended for less viscous suspensions (3).For high v i s co s i ty samples,the dose may need to be dete rmined by we i g ht with a quant i t at i ve sample tra n s fer to the dissolution vessel to ensure accura cy of the sample size int rod u ce d. High visco s i ty suspensions may also re q u i re a faster agitation rate such as 50 or 75 rpm to preve nt sample mounding at the bo t tom of the ve s s e l .
I d e a l l y,sample we i g ht / volume should re f l e ct a ty p i ca l dose of the prod u ct .Howeve r,testing a partial dose,e. g.≥ 10 -20 % of the usual prod u ct dose,is re commended rat h e r than using a surf a ct a nt to obtain sink co n d i t i o n s.
O rally Di s i nte g rating Ta b l e t s
O rally disinte g rating tablets (ODT) cre ate an in-situ s u s pension by rapidly disinte g rating ty p i cally within one m i n u te or less.Ad m i n i s t ration of ODT's may not inhere nt l y result in a faster thera peutic onset,but can circ u mve nt pro blems such as difficulty in swa l l owing traditional solid ora l dosage fo rms like tablets and ca p s u l e s.Ta s te masking (dru g co ating) is ve ry often an essential fe at u re of ODT's and thus can also be the rate dete rmining mechanism for dissolut i o n / re l e a s e.
In vitro dissolution testing should there fo re fo l l ow the p rinciples of solid oral dosage fo rms (tablets) or suspe n s i o n s (see previous sect i o n ) .The ro t ating paddle would be the m e t h od of first choice with an agitation rate of e. g.50 rp m . Higher agitation rates may be nece s s a ry in case of sample m o u n d i n g.The method can be applied to the orally disinteg rating tablets (finished prod u ct) as well as to the bulk inte rm e d i ate (in case of co ated drug powd e r / g ra n u l ate ) . A po te ntial difficulty for in vitro dissolution testing may ari s e f rom floating part i c l e s.
A single point specification is considered appropriate for ODT's with fast dissolution properties. For really fast dissolving ODT's,a disintegration test may be used in lieu of a dissolution test if it is shown to be a good discriminating method.
If taste masking (using polymer co ating) is a key aspe ct of the dosage fo rm ,a multi-po i nt profile in a neutral pH Dissolution In Vitro Release Testing … continued medium with early po i nts of analysis (e. g.≤ 5 min) may be re co m m e n d e d.It has to be noted that this early time po i nt in the profile is intended to address the taste -m a s king pro pe rties of the fo rm u l ation and may not have any re l eva n ce in te rms of the prod u ct's biopharm a ce u t i cal pro pe rt i e s.Such a dissolution cri te rion (ty p i cal ex a m p l e :≤ 10 % dissolved in 5 min) would largely depend on the taste inte n s i ty of the dru g and may enable the in vitro eva l u ation of the taste maski n g p ro pe rties whilst avoiding organoleptic measure m e nt s.
Ch ewable Ta b l e t s
In pri n c i p l e,the test proce d u re employed for chewa b l e tablets should be the same as that for regular tablets.Th i s co n cept is based on the po s s i b i l i ty that a pat i e nt might s wa l l ow the dosage fo rm without pro per chewing,in which case the drug will still need to be released to ensure the d e s i red pharm a co l og i cal action (4) .Wh e re applica b l e,te s t conditions would pre fe rably be the same as used fo r co nve ntional tablets of the same act i ve pharm a ce u t i ca l i n g re d i e nt,but be cause of the non-disinte g rating nat u re of the dosage fo rm ,t h e re may be a nece s s i ty to alter te s t conditions (e. g.i n c rease the agitation rate) and spe c i f i cations (e. g.i n c rease the test durat i o n ) .The re c i p rocat i n g cylinder (USP Ap p a ratus 3) with the addition of glass be a d s m ay also provide more "i nte n s i ve"a g i t ation for in vitro dissolution testing of chewable tablets.As another option, m e c h a n i cal bre a king of chewable tablets prior to ex po s i n g the specimen to dissolution testing could be co n s i d e re d. Whilst this option would more closely re f l e ct the administration of the prod u ct and the co rre s ponding fo rm u l ation and m a n u f a ct u ring fe at u re s,no approach for va l i d ating such a m e t h od has been re po rted in the lite rat u re or pre s e nte d d u ring the wo rk s h o p s.
Tra n s d e rmal Patc h e s
Although seve ral apparatus and proce d u res have be e n u t i l i zed to study in vitro release chara cte ristics of tra n sd e rmal patc h e s,it is desirable to avoid unnece s s a ry pro l i fe ration of dissolution test equipment .Cu rre nt co m pe n d i a l a p p a ratus include the paddle over disk/disk assembly m e t h od (USP apparatus 5/Ph . Eu r.2 . 9 . 4 . 1 ) ,the ro t at i n g cylinder (USP apparatus 6/Ph . Eu r.2 . 9 . 4 . 3 ) ,the re c i p rocat i n g disk (USP apparatus 7),and a paddle over ext ra ction ce l l m e t h od (Ph . Eu r.2 . 9 . 4 . 2 ) .
The paddle over disk proce d u re with a watch glass-patc hs c reen sandwich assembly is co n s i d e red to be the method of choice as it has been shown ex pe ri m e ntally that this p roce d u re results in almost the same release profile as other, m o re co m p l i cated apparatus for all US marke ted tra n sd e rmal patches (5).The co n f i g u ration of this assembly e n s u res that the patch is preve nted from floating during the e nt i re testing pe ri od.Special at te ntion needs to be given to the pro per positioning of the patch so that the dru g -l o a d e d s u rf a ce is ex posed to the medium.
The pH of the medium ideally should be adjusted to pH 5 -6,re f l e cting phys i o l og i cal skin co n d i t i o n s.For the same re a s o n , test te m pe rat u re is ty p i cally set at 32°C (eve n though te m pe rat u re may be higher when skin is cove re d ) . 100 rpm is co n s i d e red a ty p i cal agitation rate by Ph . Eu r. , which also allows for testing an aliquot patch sect i o n .Th e l at ter may be an appro p ri ate means of attaining sink co n d it i o n s,p rovided that cutting a piece of the patch is va l i d ate d to have no impact on the release mechanism.
Semi-solid To p i cal Dosage Fo rm s
Semi-solid to p i cal dosage fo rms include cre a m s,o i ntm e nts and gels.In vitro drug release from semi-solid to p i ca l dosage fo rms has been exte n s i vely inve s t i g ated using the Franz cell diffusion sys tem (6) with a synthetic membra n e and to some exte nt using the Enhancer cell (7) .Co m p a rat i ve studies indicate that the two ty pes of apparatus generate similar dat a .
De pending on the solubility of the drug substance,t h e re ce p tor medium may need to co ntain alcohol and/or s u rf a ct a nt .De -a e ration is cri t i cal to avoid bubble fo rm at i o n at the inte rf a ce with the membra n e.A synthetic membra n e is often used to serve as an inert suppo rt membra n e. De pending on the chara cte ristics of the drug prod u ct,i t m ay also be possible to co n d u ct the in vitro test without a s y nthetic suppo rt membrane (8) .For some oint m e nt s,t h e Franz cell has been used with and without membra n e s, resulting in no diffe re n ces in release rate re s u l t s.The dru g release chara cte ristics usually fo l l ow the Higuchi model (9) . As with tra n s d e rmal prod u ct s,the test te m pe rat u re is ty p ically set at 32°C to re f l e ct the usual skin te m pe rat u re.Dev i ations might be justified in case of prod u cts for specific site s of act i o n ,e. g.vaginal creams may be te s ted at 37°C.
I d e a l l y,sample we i g ht / volume should re f l e ct a ty p i ca l dose of the prod u ct .Howeve r,it is pre fe rable to use a part i a l dose rather than adding a surf a ct a nt or alcohol to the re ce p tor medium in order to obtain sink co n d i t i o n s.
No co m pendial apparat u s,p roce d u res or re q u i re m e nt s for in vitro release testing of semi-solid to p i cal dosage fo rm s h ave been descri bed in re l eva nt Ph a rm a co poeias to date. Howeve r,F D A's Gu i d a n ce for Industry on Scale Up and Po s t Ap p roval Changes for Semisolid (SUPAC-SS) dosage fo rm s d e s c ri bes the release rate studies using the ve rt i cal diffusion cell (Franz cell) proce d u re and re q u i res in vitro release rate co m p a rison be tween pre-change and post-change produ cts for approval of SUPAC re l ated changes (10) .
Be cause of the value and impo rt a n ce of release rate,it is highly desirable to dete rmine the release data of semisolid dosage fo rms (11) .Th e re is also a need to develop co m pe ndial test method ( s ) .It is ex pe cted that given the va ri e ty of See Dissolution In Vitro Release Testing… continued page 10 Dissolution In Vitro Release Testing … continued fo rm u l at i o n s,s i tes of applicat i o n s,and the va ri e ty of re l e a s e rates for semi-solid to p i cal dosage fo rm s,no single te s t p roce d u re would be suitable for the deve l o p m e nt,b i o p h a rm a ce u t i cal chara cte ri z ation and quality co nt rol of all semisolid to p i cal dosage fo rm s.Based on the fo re g o i n g s t ate m e nt,the inclusion of a single apparatus in pharm aco poeias may not be the desired solution.Howeve r,t h e Franz cell (7) is co n s i d e red the most promising apparatus fo r i nve s t i g ation of post approval changes.
Su p po s i to ri e s
In pri n c i p l e, for hyd rophilic suppo s i to ries that re l e a s e the drug by dissolving in the re ctal fluids, the baske t, p a d d l e, or flow -t h rough cell can all be used. L i pophilic suppo s i to ries release the drug after melting in the re ctal cav i ty,and are significa ntly affe cted by the re ctal te m pe rat u re, re po rted as ty p i cally 36 -37.5 °C (12). In vitro release testing also re q u i res kn owledge of the melting po i nt / range of the prod u ct being te s te d.The te s t te m pe rat u re should take into co n s i d e ration phys i o l ogi cal conditions but may also be at or slightly above the melting po i nt,e. g. at 37 -38.5 °C (which can be justified e. g.for suppo s i to ri e s, used for pat i e nts with feve r ) .
After melting,d rug will have to partition be tween the l i pophilic base and the re ce p tor fluid.This may lead to a d i s t ribution equilibrium be tween the two phases rat h e r than co m p l e te dissolution.For this re a s o n , sink co n d itions during the test are essential in order to simulate the in vivo situat i o n ,w h e re absorption across the re ct a l m e m b rane is co ntinuously reducing the co n ce nt rat i o n of the drug in the re ctal fluids.
The use of membranes in the test is in pri n c i p l e at t ra ct i ve since it is the most elegant way to obtain a f i l te red clear solution for immediate assay. Howeve r, i t i nt rod u ces an artificial process of tra n s po rt and is thus, in genera l , not re co m m e n d e d.
For lipophilic suppo s i to ri e s, a modified baske t m e t h od, a paddle method with a wired screen and a s i n ker (13) and, a modified flow -t h rough cell with a s pecific dual chamber suppo s i to ry cell (Ph . Eu r. 2 . 9 . 3 . -6 . ) h ave all been re co m m e n d e d. In order to achieve the s pecified te m pe rat u re in the test ce l l , the te m pe rat u re in the water bath may have to be set up to 5 °C higher. E x pe ri e n ce with the co m pendial flow through ce l l has shown that it may generate highly va riable dat a due to the be h avior of the suppo s i to ry in the cell (14) , in particular for fo rm u l ations co ntaining spre a d i n g a g e nt s. Dev i ating from the general re co m m e n d at i o n , i . e. use of membrane-based phys i co -c h e m i cal te s t m e t h ods (15) may be co n s i d e red for lipophilic suppo s ito ry fo rm u l ations exhibiting this kind of be h av i o r.
No one single test method will be suitable for all suppository formulations. However, from the set of available methods described above it should be possible to select an adequate in vitro release test in most cases. Recommendation of a method of first choice is inappropriate,based on the variety of formulation characteristics of suppositories.However, when starting development of an in vitro dissolution/release test, it might be advantageous to begin with the basket or paddle in case of hydrophilic and with the modified flow-through cell in case of lipophilic suppositories.
Vaginal dosage forms are often designed for local therapeutic effects.Nevertheless, if an in vitro release test is to be designed, the recommendations for suppositories may be followed.
Liquid Filled Ca p s u l e s
Liquid filled capsules can consist of either,hyd rophilic or l i pophilic fo rm u l at i o n s.In the case of lipophilic fo rm u l at i o n s,t h ey may or may not include a surf a ct a nt for selfemulsifying purpo s e s.The USP re commends a dissolution test proce d u re using the ro t ating paddle method (Ap p aratus 2) with minimum amount of surf a ct a nt,if needed (e. g. , dissolution of va l p roic acid ca p s u l e s,m e t h oxsalen ca p s u l e s ) . If the liquid filled capsule co ntains a water soluble base, then addition of surf a ct a nt is generally not needed, h oweve r,this is a function of solubility of the act i ve pharm ace u t i cal ingre d i e nt as well as the fo rm u l ation itself.Th e ro t ating paddle can have disadva ntages for some liquid filled capsule fo rm u l at i o n s,as it might be difficult to ke e p the fo rm u l ation immersed.Al s o,emulsified fo rm u l at i o n s m i g ht separate at the liquid-vessel-air inte rf a ce and/or fo rm u l ations could adhere to paddle or be a ker wa l l s.
The modified dual chamber flow through ce l l ,as re co mmended for lipophilic suppo s i to ries (Ph . Eu r.2.9.3.-6.) is co n s i d e red an appro p ri ate test apparatus for liquid filled ca p s u l e s.It can be run as an open or a closed (this may be i m po rt a nt for self-emulsifying fo rm u l ations) sys te m .O n e po te ntial disadva ntage is that screens might be bloc ke d d u ring the te s t .
Other apparatus have also been successfully used,such as the ro t ating basket (which keeps the fo rm u l ation immersed, h owever might result in bloc ked meshes) or the re c i p rocating cylinder (which offers good mechanical agitation but a l i m i ted media vo l u m e ) .
Es pecially during the deve l o p m e nt phase,a range of te s t media should be used to chara cte ri ze and understand the fo rm u l ation chara cte ri s t i c s.In the case of lipid filled ca p s u l e s, e n zymes in addition to surf a ct a nts may be nece s s a ry to simul ate digestion if this is a rate-limiting step for dissolution and a b s o rption in vivo.The adva ntage of using lipases is that it m o re closely re f l e cts phys i o l og i cal co n d i t i o n s.The disadva ntages are that it can be ex pe n s i ve and labor inte n s i ve when used as a routine te s t,and ty p i cally leads to higher va ri a b i l i ty.
No one single test method will be suitable for all liquid
Pa re nte ra l s :I m p l a nts and Mi c ro p a rt i c u l ate Fo rm u l at i o n s
The co m pendial and the modified flow -t h rough cell have been used successfully for implants and micro p a rt i c u l ate fo rm u l at i o n s.The co m pendial flow -t h rough apparatus is m odified with re g a rd to the inner diameter to suit the s pecial pro pe rties for testing pare nte ra l s,i . e.a low volume of fluid is used in the acce p tor co m p a rt m e nt .The flow rate of the medium has to be set ve ry slow.Use of HPLC pumps m ay be co n s i d e red to provide the nece s s a ry accura cy and p recision at ve ry low flow rate s.In this case the flow -t h ro u g h s ys tem may need to be re-designed with small inte rn a l d i a m e ter tubing.I nte rm i t te nt flow might also be an option. St atic or ro t ating bottles have also been used for in vitro release te s t i n g.
As tests are often run over a long time pe ri od (e. g.s eve ra l weeks to months) measures have to be taken to co m pe n s ate against eva po rat i o n .Suitable pre s e rvat i ves may be added to p reve nt microbial co nt a m i n at i o n .St a n d a rd pre s e rvat i ve s, including ce tylammonium bro m i d e,be n z a l konium chlori d e, p a ra be n s,phenol deri vat i ves and merc u ry salts,along with a p p ro p ri ate co n ce nt rations to be used,a re listed in many p h a rm a ce u t i cal text boo k s.The selection has to be based on c ri te ria such as co m p at i b i l i ty with the act i ve pharm a ce u t i ca l as well as other fo rm u l ation ingre d i e nts and the pH of the test medium.Issues with these co m pounds include their i o n i z ation pro pe rt i e s,p hys i co -c h e m i cal inte ra ctions or a n a l y t i cal inte rfe re n ce s.0.1% sodium azide has also be e n u s e d,but due to safe ty co n ce rn s,this pre s e rvat i ve cannot be g e n e rally re co m m e n d e d.
The co m position of the medium should take into co n s i d e ration the osmolari ty,pH and buffer ca p a c i ty of the fluids at the s i te of administrat i o n ,which are usually assumed to re s e m b l e t h at of plasma (or muscle) but with lower buffer ca p a c i ty. Howeve r,the main challenges with this ty pe of dosage fo rm a re to dete rmine the appro p ri ate duration of the test and the times at which samples are to be drawn in order to chara cte ri ze the release profile adequate l y.The po s s i b i l i ty of ru n n i n g the test under acce l e rated conditions is at t ra ct i ve,and has been successfully applied through elevated test te m pe rat u re s ( even above glass transition te m pe rat u res of the po l y m e r s i nvo l ved) and at pH-values offe ring faster drug release (18) .
To eva l u ate whether acce l e rated test data are pre d i ct i ve,t h e Weibull shape factor should be co n s i d e red (19) .Ve ri f i cation of the va l i d i ty of using acce l e rated test conditions could also include an Arrhenius plot afte r obtaining release rate co n s t a nts from lineari zed release profiles (20) .
For real-time (long duration) and acce l e rated te s t s, e m p l oying po te ntially adverse te m pe rat u res or pH va l u e s, the stability of the act i ve ingre d i e nt,has to be taken into a c co u nt,either analytically or through appro p ri ate algorithms when ca l c u l ating release dat a . 
Ch ewing Gu m s
In the case of chewing gums,the inte n s i ty and fre q u e n cy of shearing fo rce s / a ctivities (i.e."c h e w i n g"a ction) can have a l a rge influence on drug release rate.The Eu ro pean Ph a rm aco poeia provides a description of a stainless steel 3-pisto na p p a rat u s,which is re q u i red for testing of "Me d i cate d Chewing Gu m s"( Ph . Eu r.2.9.25) (16) .The test is ty p i ca l l y o pe rated at 37 °C and at 60 cyc l e s / m i n .Test media with a pH 6 are commonly used,s i n ce this pH co rre s ponds to re po rte d (17) saliva pH values of 6.4 (adults) or 7.3 (childre n ) .In part i cular during deve l o p m e nt,it is re commended to keep the "chewing re s i d u e"for later analys i s / a s s ay.Howeve r,to date t h e re has been insufficient inte rn ational ex pe ri e n ce with this apparatus to draw a firm conclusion about its suitability.
Powders, Granules, Solid Solutions and Solid Dispersions
The flow through apparatus offers specific sample ce l l s for studying drug release from powder and gra n u l a r dosage fo rm s.Howeve r,it is impo rt a nt to note that the dissolution be h avior of these dosage fo rms may be gre at l y i n f l u e n ced by their we t t a b i l i ty, s u rf a ce area and particle size d i s t ri b u t i o n .Th u s,the in vitro release test results co n s t i t u te one of a group of phys i coc h e m i cal para m e ters needed to c h a ra cte ri ze the prod u ct .For powd e r s,e s pecially when exhibiting poor we t t a b i l i ty,it may be nece s s a ry to add a s u rf a ct a nt to the dissolution medium to obtain re p roducible dissolution re s u l t s. Ca re should be taken to use a l evel of surf a ct a nt that does not increase the solubility of the drug to the exte nt where the test is no longer discri m in ato ry.In ce rtain ca s e s,a phys i cal mixt u re of the powd e r with glass beads and/or substance s,which enco u ra g e we t t i n g,m ay be used.
Solid solutions and dispersions may be pre s e nted in ora l dosage fo rms such as capsules and tablets.If this is the ca s e, their in vitro release chara cte ristics can be dete rm i n e d using the same methods ty p i cally used to chara cte ri ze the release from solid oral dosage fo rm s.Solid solutions and d i s persions often lead to a supe r s at u ration of the medium. Th e re fo re for these specific ty pes of fo rm u l at i o n s,d i s s o l ution tests under non-sink conditions can be a pre d i ct i ve tool during fo rm u l ation deve l o p m e nt as well as for batc hto -b atch quality co nt ro l .Es pecially during prod u ct deve lo p m e nt,running the in vitro release test somewhat longer, e. g.for up to four hours,should be co n s i d e red to assess the po te ntial for pre c i p i t at i o n .
